Trump announces reforms to accelerate access to psychedelic drug treatments
President Trump signed an executive order to accelerate FDA review of psychedelic treatments like ibogaine for PTSD and addiction.
SOURCE CHECK
TAP FOR WHYHost credibility · The Guardian85/100 HIGH
42 stories · 84–86 · updated Sep 25, 2026
This article1 analysis · Apr 18, 2026
Republished with credit
Republished from Reuters, with credit to the original publisher.
Reuters96/100 HIGH
104 stories · 95–96 · updated Sep 24, 2026
This is Reuters's own score, and this article is credited to Reuters. The host score in the Source Check is The Guardian's.
Published Apr 18, 2026
tl;dr
President Trump signed an executive order to expedite FDA review and federal research for psychedelic treatments like ibogaine, specifically targeting PTSD and opioid addiction.
Community verdict
20 VOTES
Rated by people, not pundits.● OPEN
People in this story
SWIPE →
Discussion · 0
What's your take?
Loading comments…